Maja Brøgger Thomassen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Maja Brøgger Thomassen has a total of 46 co-authors. Here are the top co-authors by number of shared publications:
- Klaes Vincent Lenbroch
Institute of Clinical Medicine, Aarhus University Hospital, Denmark; Department of Cardiology, Aarhus University Hospital, Aarhus, Denmark
3 shared publications - Maiken Stilling
Aarhus University Hospital
3 shared publications - Mats Bue
Department of Clinical Medicine, Aarhus University, Aarhus, Denmark
3 shared publications - Niels Moeslund
Institute of Clinical Medicine, Aarhus University Hospital, Denmark; Department for Heart, Lung, and Vascular Surgery, Aarhus University Hospital, Denmark
3 shared publications - Alan McCheyne
Paediatric Heart Unit, Institute of Transplantation, Freeman Hospital, Newcastle upon Tyne, the United Kingdom of Great Britain and Northern Ireland
2 shared publications - James Warburton
Paediatric Heart Unit, Institute of Transplantation, Freeman Hospital, Newcastle upon Tyne, UK
2 shared publications
Latest Publications
- Open Access
- 24 September 2026
- Published by Elsevier in The Journal of Heart and Lung Transplantation
Myocardial metabolism during DCD heart donation and transplantation assessed by microdialysis
- 24 September 2026
- Published by Elsevier in The Journal of Heart and Lung Transplantation
Open AccessMyocardial metabolism during DCD heart donation and transplantation assessed by microdialysis
- Open Access
- 7 October 2025
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 45 (3) , 494-512
HOPE for children: successful pediatric DCD heart transplantation using hypothermic oxygenated perfusion
- 7 October 2025
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 45 (3) , 494-512
Open AccessHOPE for children: successful pediatric DCD heart transplantation using hypothermic oxygenated perfusion
- 4 August 2020
- Published by Wolters Kluwer Health in Journal of Bone and Joint Surgery
- Vol. 102 (21) , 1857-1864
Timing of Antimicrobial Prophylaxis and Tourniquet Inflation
Background: Tourniquets are widely used during extremity surgery. In order to prevent surgical site infection, correct timing of antimicrobial prophylaxis and tourniquet inflation is important. We aimed to evaluate the time for which the free drug concentration of cefuroxime is maintained above the minimum inhibitory concentration (t > MIC) in porcine subcutaneous adipose tissue and calcaneal cancellous bone during 3 clinically relevant tourniquet application scenarios. Methods: Twenty-four female Danish Landrace pigs were included. Microdialysis catheters were placed bilaterally for sampling of cefuroxime concentrations in calcaneal cancellous bone and subcutaneous adipose tissue, and a tourniquet was applied to a randomly picked leg of each pig. Subsequently, the pigs were randomized into 3 groups to receive 1.5 g of cefuroxime by intravenous injection 15 minutes prior to tourniquet inflation (Group A), 45 minutes prior to tourniquet inflation (Group B), and at the time of tourniquet release (Group C). The tourniquet duration was 90 minutes in all groups. Dialysates and venous blood samples were collected for 8 hours after cefuroxime administration. Cefuroxime and various ischemic marker concentrations were quantified. Results: Cefuroxime concentrations were maintained above the clinical breakpoint MIC for Staphylococcus aureus (4 µg/mL) in calcaneal cancellous bone and subcutaneous adipose tissue throughout the 90-minute tourniquet duration in Groups A and B. Cefuroxime administration at the time of tourniquet release (Group C) resulted in concentrations of >4 µg/mL for approximately of 3.5 hours in the tissues on the tourniquet side. Furthermore, tourniquet application induced ischemia (increased lactate:pyruvate ratio) and cell damage (increased glycerol) in subcutaneous adipose tissue and calcaneal cancellous bone. Tissue ischemia was sustained for 2.5 hours after tourniquet release in calcaneal cancellous bone. Conclusions: Administration of cefuroxime (1.5 g) in the 15 to 45-minute window prior to tourniquet inflation resulted in sufficient concentrations in calcaneal cancellous bone and subcutaneous adipose tissue throughout the 90-minute tourniquet application. Furthermore, tourniquet-induced tissue ischemia fully resolved 2.5 hours after tourniquet release. Clinical Relevance: Cefuroxime administration 15 to 45 minutes prior to tourniquet inflation seems to be a safe window. If the goal is to maintain postoperative cefuroxime concentrations above relevant MIC values, our results suggest that a second dose of cefuroxime should be administered at the time of tourniquet release.
- 4 August 2020
- Published by Wolters Kluwer Health in Journal of Bone and Joint Surgery
- Vol. 102 (21) , 1857-1864
Timing of Antimicrobial Prophylaxis and Tourniquet Inflation
Background: Tourniquets are widely used during extremity surgery. In order to prevent surgical site infection, correct timing of antimicrobial prophylaxis and tourniquet inflation is important. We aimed to evaluate the time for which the free drug concentration of cefuroxime is maintained above the minimum inhibitory concentration (t > MIC) in porcine subcutaneous adipose tissue and calcaneal cancellous bone during 3 clinically relevant tourniquet application scenarios. Methods: Twenty-four female Danish Landrace pigs were included. Microdialysis catheters were placed bilaterally for sampling of cefuroxime concentrations in calcaneal cancellous bone and subcutaneous adipose tissue, and a tourniquet was applied to a randomly picked leg of each pig. Subsequently, the pigs were randomized into 3 groups to receive 1.5 g of cefuroxime by intravenous injection 15 minutes prior to tourniquet inflation (Group A), 45 minutes prior to tourniquet inflation (Group B), and at the time of tourniquet release (Group C). The tourniquet duration was 90 minutes in all groups. Dialysates and venous blood samples were collected for 8 hours after cefuroxime administration. Cefuroxime and various ischemic marker concentrations were quantified. Results: Cefuroxime concentrations were maintained above the clinical breakpoint MIC for Staphylococcus aureus (4 µg/mL) in calcaneal cancellous bone and subcutaneous adipose tissue throughout the 90-minute tourniquet duration in Groups A and B. Cefuroxime administration at the time of tourniquet release (Group C) resulted in concentrations of >4 µg/mL for approximately of 3.5 hours in the tissues on the tourniquet side. Furthermore, tourniquet application induced ischemia (increased lactate:pyruvate ratio) and cell damage (increased glycerol) in subcutaneous adipose tissue and calcaneal cancellous bone. Tissue ischemia was sustained for 2.5 hours after tourniquet release in calcaneal cancellous bone. Conclusions: Administration of cefuroxime (1.5 g) in the 15 to 45-minute window prior to tourniquet inflation resulted in sufficient concentrations in calcaneal cancellous bone and subcutaneous adipose tissue throughout the 90-minute tourniquet application. Furthermore, tourniquet-induced tissue ischemia fully resolved 2.5 hours after tourniquet release. Clinical Relevance: Cefuroxime administration 15 to 45 minutes prior to tourniquet inflation seems to be a safe window. If the goal is to maintain postoperative cefuroxime concentrations above relevant MIC values, our results suggest that a second dose of cefuroxime should be administered at the time of tourniquet release.
- 14 January 2020
- Published by Wiley in Journal of Orthopaedic Research
- Vol. 38 (8) , 1793-1799
Local concentrations of gentamicin obtained by microdialysis after a controlled application of a GentaColl sponge in a porcine model
Local treatment with gentamicin may be an important tool in the prevention and treatment of surgical site infections in high‐risk procedures and patients. The aim of this study was to evaluate the pharmacokinetic profile of gentamicin in bone and surrounding tissue, released from a controlled application of a GentaColl sponge in a porcine model. In eight female pigs, a GentaColl sponge of 10 × 10 cm (1.3 mg gentamicin/cm2) was placed in a cancellous bone cavity in the proximal tibia. Microdialysis was used for sampling of gentamicin concentrations over 48 hours from the cavity with the implanted GentaColl sponge, cancellous bone parallel to the cavity over and under the epiphyseal plate, cortical bone, the intramedullary canal, subcutaneous tissue, and the joint cavity of the knee. Venous blood samples were obtained as reference. The main finding was a mean peak drug concentration (95% CI) of gentamicin in the cancellous bone cavity containing the implanted GentaColl sponge of 11 315 (9049‐13 581) μg/mL, persisting above 1000 μg/mL until approximately 40 hours after application. Moreover, the concentrations were low (<1 μg/mL) in the surrounding tissues as well as in plasma. The mean peak gentamicin concentration from the cancellous bone cavity after a controlled application of a GentaColl sponge was high and may be adequate for the prevention of biofilm formation. However, high MIC strains and uncontrolled application of the GentaColl sponge may jeopardize this conclusion.
- 14 January 2020
- Published by Wiley in Journal of Orthopaedic Research
- Vol. 38 (8) , 1793-1799
Local concentrations of gentamicin obtained by microdialysis after a controlled application of a GentaColl sponge in a porcine model
Local treatment with gentamicin may be an important tool in the prevention and treatment of surgical site infections in high‐risk procedures and patients. The aim of this study was to evaluate the pharmacokinetic profile of gentamicin in bone and surrounding tissue, released from a controlled application of a GentaColl sponge in a porcine model. In eight female pigs, a GentaColl sponge of 10 × 10 cm (1.3 mg gentamicin/cm2) was placed in a cancellous bone cavity in the proximal tibia. Microdialysis was used for sampling of gentamicin concentrations over 48 hours from the cavity with the implanted GentaColl sponge, cancellous bone parallel to the cavity over and under the epiphyseal plate, cortical bone, the intramedullary canal, subcutaneous tissue, and the joint cavity of the knee. Venous blood samples were obtained as reference. The main finding was a mean peak drug concentration (95% CI) of gentamicin in the cancellous bone cavity containing the implanted GentaColl sponge of 11 315 (9049‐13 581) μg/mL, persisting above 1000 μg/mL until approximately 40 hours after application. Moreover, the concentrations were low (<1 μg/mL) in the surrounding tissues as well as in plasma. The mean peak gentamicin concentration from the cancellous bone cavity after a controlled application of a GentaColl sponge was high and may be adequate for the prevention of biofilm formation. However, high MIC strains and uncontrolled application of the GentaColl sponge may jeopardize this conclusion.